Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
PSTI develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases.
PSTI also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS.
PSTI has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication.
Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
June 17, 2021
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector rallied after a two (2) session flogging
June 16, 2021
RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results
June 16, 2021
Q2/21 Earnings - (LPS - loss-per-share) Results
June 14, 2021
RegMed Investors’ (RMi) closing bell: winner, winner, chicken dinner
June 14, 2021
RegMed Investors’ (RMi) pre-open: The ups of the cell and gene therapy stocks has an impact on the direction of the sector
June 11, 2021
RegMed Investors’ (RMi) closing bell: another positive session to end the week
June 11, 2021
RegMed Investors’ (RMi) pre-open: the sector revels in news
June 10, 2021
RegMed Investors’ (RMi) closing bell: the trend is still the cell and gene therapy’s sector friend
June 7, 2021
RegMed Investors’ (RMi) closing bell: not crying about the sector high
June 4, 2021
RegMed Investors’ (RMi) closing bell: depths and peaks as experienced by the week
35 companies, 1 interpreter!
Insight, foresight and recommendation
Pluristem (PSTI) – Opened 2018 at $1.44, saw a high of $1.61 and started 2/1 at $1.47 with 2/21 having slipped to $1.38. News is always an appreciator that is never followed through ... PSTI needs to refine its communication to shareholders and operates on assumptions. With $36M of cash on hand and pivotal studies (three) being paid for by grants, estimates assume a quarterly cash burn rate of $8M – I am still a critic expecting data readouts from three of its clinical programs in 2018. Traders "play" the shares - too often ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2021 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.